Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 54

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 54
---
 provide blood and tissue banks with highly sensitive and specific tests       
 to ensure safe transfusions and donations. Grifols assays are based on        
 nucleic acid amplification techniques (NAT), which enable the detection       
 of viruses such as HIV, hepatitis B and C, as well as emerging viruses like   
 Zika and West Nile, and parasites such as those that cause babesiosis.        
 Grifols also develops blood typing platforms to ensure compatibility          
 between donors and recipients. These gel-based assays not only identify       
 major blood groups like ABO and Rh but also detect less common blood          
 groups that are still highly relevant to human pathologies, such as sickle    
 cell anemia and cancer.                                                       
 According to the World Health Organization (WHO), 50% of donated              
 blood is collected in emerging countries, which account for 80% of the        
 global population¹. These countries lack basic measures to ensure safe        
 transfusions and donations are not universally implemented. Grifols is        
 actively working to expand its transfusion diagnostic solutions in emerging   
 markets, including the Philippines, India, Egypt and Indonesia. This is       
 also the case in China, where Grifols collaborates with Shanghai RAAS         
 to progressively contribute to raising transfusion safety standards in the    
 country’s blood donation centers.                                             
 In 2024, Grifols’ NAT technology was used to test more than 38 million        
 blood donations, and the company supplied over 71.5 million gel-based         
 blood typing cards.                                                           
 The first free direct-to-consumer program                                     
 for detecting Alpha-1 Deficiency (AATD)                                       
 In 2023, Grifols launched the AlphaID™ At Home Genetic Health Risk            
 Service, the first free, direct-to-consumer program for U.S. residents        
 designed to facilitate genetic detection of Alpha-1 Antitrypsin Deficiency    
 (AATD). This condition, which has symptoms similar to COPD, is estimated      
 to affect about 1 in every 2,500 Americans.                                   
 Using AlphaID™ At Home, individuals can assess their risk of developing       
 lung and/or liver disease associated with Alpha-1 using a simple saliva       
 sample, without needing to visit a healthcare professional.                   
 As of May 2024, nearly 68,000 AlphaID™ At Home kits had been                  
 requested. Additionally, the AlphaID™ kit, developed by Progenika, has        
 been used in medical practices and across many other countries, enabling      
 the detection